CDK7 and cancer: In line with the DepMap analysis, higher expression of CDK7 is associated with worse progression-free survival (PFS) for several cancer types including kidney renal papillary and kidney clear cell carcinoma (KIRP and KIRC, respectively), low-grade gliomas (LGG), liver hepatocellular carcinoma (LIHC), and thyroid carcinoma (THCA) (Fig. 1d–f, Supplementary Data 2).